Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIRCETTE vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women aged ≥15 years who have reached menarche and desire contraception
Prevention of pregnancy
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass hepatic metabolism, conjugated to sulfate and glucuronide. Desogestrel: prodrug converted to active metabolite etonogestrel via CYP2C9 and CYP3A4; further metabolized by reduction and glucuronidation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Desogestrel: >95% (albumin, SHBG); ethinyl estradiol: >97% (albumin)
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Desogestrel: 1.5 L/kg; ethinyl estradiol: 2.9 L/kg
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Desogestrel (as etonogestrel): 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism)
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No specific dose adjustment recommended. Use with caution in severe renal impairment due to potential fluid retention.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in severe hepatic disease (Child-Pugh class C) or liver tumors. For mild to moderate impairment (Child-Pugh A-B), use with caution; contraindicated if liver function tests are persistently abnormal.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated in prepubertal females. Safety and efficacy in postmenarchal adolescents established based on adult studies.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Contraindicated in postmenopausal women. Not indicated for use in elderly due to lack of efficacy for contraception.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from COC use, especially in women >35 years old who smoke ≥15 cigarettes/day. Do not prescribe to women who smoke and are over 35.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thrombotic disorders (VTE, MI, stroke), especially in smokers and women with hypertension or other risk factors.,Liver disease: discontinue if jaundice or impaired liver function develops.,Elevated blood pressure: monitor and discontinue if hypertension develops.,Gallbladder disease: possible increased risk.,Carbohydrate and lipid metabolism: monitor in diabetic or hyperlipidemic patients.,Headache: may exacerbate migraine or cause new-onset headache.,Uterine bleeding: irregular bleeding may occur.,Depression: discontinue if significant depression occurs.,Ocular effects: discontinue if sudden partial/complete vision loss occurs.,Carcinoma: possible increased risk of breast/cervical cancer, but evidence uncertain.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Carcinoma of endometrium or other known/suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Migraine with aura (current or history) in women over 35
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions known; however, grapefruit juice may increase estrogen levels via CYP3A4 inhibition, though clinical significance is low. Avoid St. John's wort as it induces metabolism of ethinyl estradiol and desogestrel, potentially reducing contraceptive efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/third trimester exposure may cause fetal adrenal suppression, virilization of female fetus, and metabolic disturbances.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted into breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infant (adrenal suppression, hormonal imbalance). Contraindicated during breastfeeding per manufacturer.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) would theoretically require dose increase, but use is not recommended.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Mircette is a monophasic oral contraceptive containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. It has a shorter hormone-free interval (2 days of placebo) than traditional 7-day placebo regimens, which may reduce breakthrough ovulation and improve suppression of ovarian activity. Counsel patients that the first 7 days of the initial cycle may require a backup method. Desogestrel has low androgenicity and may improve acne. Use with caution in patients with migraine with aura or increased cardiovascular risk.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet at the same time daily; missed pills increase pregnancy risk.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Mircette may reduce menstrual bleeding and cramping; do not skip pills during withdrawal bleeding.,Smoking while on this pill increases risk of blood clots, especially in women over 35.,Some antibiotics and anticonvulsants may reduce effectiveness; inform your healthcare provider of all medications.,Do not take if you have a history of blood clots, certain cancers, or liver disease.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIRCETTE vs ALYACEN 7/7/7, answered by our medical review team.
MIRCETTE is a Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIRCETTE and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIRCETTE is: One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIRCETTE and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIRCETTE is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.